Companion diagnostics for NSAIDS and donepezil for treating specific subpopulations of patients suffering from Alzheimer's disease

A method for identifying a patient response to treatment for Alzheimer's Disease with a non-steroidal anti-inflammatory drug (NSAID) comprising:

• obtaining a blood, plasma, or serum sample from the patient;
• determining a presence of a proinflammatory endophenotype associated with Alzheimer's disease in the blood, plasma, or serum sample of the patient;
• using the proinflammatory endophenotype to detect a treatment response from the patient;
• determining a treatment type for the detected treatment response from the patient, the determining of the treatment type including:
• ranking the expressions of the proinflammatory endophenotype proteins and correlating them to the NSAID;
• ranking the expressions of the proinflammatory endophenotype proteins in the following order:
• CRP, TNFα, IL5, IL6, IL7, IL18 and IL10, and correlating them to a response to naproxen;
• or
• ranking IL10, CRP, IL6, IL18, IL7, TNFα, and IL5, and correlating them to a response to rofecoxib;
• and
• administering the NSAID, naproxen, or rofecoxib to a responder or a stable treatment response phenotype group patient based upon the determined treatment type.